Partnership to develop
immunotherapy treatments for respiratory allergies using DBV’s skin patch,
Viaskin®
Download official press release (141.5 KB)
ANTONY and BAGNEUX, France, 16 May 2013 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and Stallergenes S.A. (Euronext Paris CAC small), worldwide leader in allergen immunotherapy, announced today that they have entered into a strategic research partnership.
This partnership combines Stallergenes’ world class know-how in respiratory allergies with DBV’s Viaskin, a unique platform allowing for epicutaneous desensitization. DBV will conduct all preclinical work, up to proof-of-concept studies using Viaskin® and Stallergenes’ aeroallergens. Stallergenes will finance all of DBV’s research on these aeroallergens and will have development and commercialization rights. In the coming months, the parties will enter into license agreements for each aeroallergen, defining the opt-in terms for development and commercialization.
Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said: “The agreement with Stallergenes is very much in line with our strategy to expand our Viaskin® proprietary platform beyond food allergies. Stallergenes is an ideal partner and has the expertise in respiratory allergies, a major health issue affecting approximately 20% of the general population. Both companies share a passion for innovation, and I strongly believe that the combination of our respective strengths will lead to best-in-class treatments for the benefit of patients.”
Dr. Roberto Gradnik, CEO of Stallergenes, said: “We are very pleased to team up with DBV Technologies, a company that is developing innovative products designed to deliver allergens with epicutaneous immunotherapy. This collaboration will reinforce our deep expertise in allergen immunotherapy, well-established for more than 50 years, and demonstrates our continuous focus on innovation. Our expertise combined with DBV’s new route of administration will give the opportunity to patients, especially young children, to benefit from a new innovative solution in allergen immunotherapy.”
